Stockscreener 앱 받기
3.48
4.66%
-0.17
시장 영업 전:
3.36
-0.12
-3.45%
Nrx Pharmaceuticals Inc 주식(NRXP)의 최신 뉴스
Squarepoint Ops LLC Makes New Investment in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) - Defense World
NRX Pharmaceuticals Submits FDA Application for NRX-100 - TipRanks
New to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor Platforms - USA Today
NRx Pharmaceuticals’ (NRXP) Buy Rating Reaffirmed at D. Boral Capital - Defense World
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network - Yahoo Finance
NRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network - The Globe and Mail
NRX Pharmaceuticals: Strategic Positioning and Market Potential Drive Buy Rating - TipRanks
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025 - mx.advfn.com
NRx Pharmaceuticals files for preservative-free ketamine By Investing.com - Investing.com South Africa
$750 Million Market Projected to Reach $3.35 Billion Globally - openPR.com
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine - Yahoo Finance
Why Ciena Stock Is Plummeting Today - The Globe and Mail
$750 Million Market Projected to Reach $3.35 Billion Globally in 2034 for Abbreviated New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV Ketamine - TipRanks
NRx Pharmaceuticals files for preservative-free ketamine - Investing.com Australia
NRXP Advances FDA Application for IV Ketamine With Preservative-Free Formulation | NRXP Stock News - GuruFocus
NRX Pharmaceuticals Seeks FDA's Priority Review for Preservative-Free IV Ketamine - marketscreener.com
$3.35B Ketamine Market Opportunity: NRx Aims to Solve Critical Drug Shortage with New FDA Filing - Stock Titan
Why Overall Consumer Confidence Is Critical to the Markets You Follow - The Globe and Mail
Public market insider buying at Tourmaline Oil (TOU) - The Globe and Mail
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network - MSN
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Announces $10.3M Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval - Yahoo Finance
NRx Pharmaceuticals (NASDAQ: NRXP) Announces $10.3M Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval - TipRanks
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition - Yahoo Finance
NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition - financial-news.co.uk
Analysts Set NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Target Price at $28.50 - Defense World
Stocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock Chatter - MSN
NRX Pharmaceuticals Announces $7.8M Debt Financing Deal - TipRanks
NRx Pharmaceuticals (NASDAQ: NRXP) to Present at Wall Street Conference on May 21 - financial-news.co.uk
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) to Present at Wall Street Conference on May 21 - Yahoo Finance
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida - GuruFocus
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q1 2025 Earnings Call Transcript - Insider Monkey
NRx Pharmaceuticals Earnings Call Highlights Progress and Optimism - TipRanks
NRX Pharmaceuticals: A Promising Investment with Innovative Growth and Strong Financial Outlook - TipRanks
NRx Pharmaceuticals (NASDAQ:NRXP) Earns Buy Rating from D. Boral Capital - Defense World
NRx Pharmaceuticals (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE’s Strategic Kadima Agreement - TipRanks
NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup - TipRanks
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup - Yahoo Finance
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 20 - GuruFocus
HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions - The Malaysian Reserve
Earnings call transcript: NRx Pharmaceuticals targets profitability by end of 2025 in Q1 2025 - Investing.com Canada
NRx Pharmaceuticals Reports Q1 2025 Results and Strategic Progress - TipRanks
Transcript : NRx Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
NRX Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
0.92%
7.75%
자본화:
|
볼륨(24시간):